Enasidenib

Enasidenib
Clinical data
Trade names	Idhifa
Other names	AG-221
AHFS/Drugs.com	Monograph
MedlinePlus	a617040
License data	US DailyMed: Enasidenib;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
Drug class	IDH2 inhibitor
ATC code	L01XM01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only;
Identifiers
CAS Number	1446502-11-9;
PubChem CID	89683805;
DrugBank	DB13874;
ChemSpider	38772329;
UNII	3T1SS4E7AG;
KEGG	D10901; as salt: D11044;
ChEBI	CHEBI:145374;
ChEMBL	ChEMBL3989908;
PDB ligand	69Q (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID801027942 ;
Chemical and physical data
Formula	C19H17F6N7O
Molar mass	473.383 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(CNC1=NC(=NC(=N1)NC2=CC(=NC=C2)C(F)(F)F)C3=NC(=CC=C3)C(F)(F)F)O;
	InChI InChI=InChI=1S/C19H17F6N7O/c1-17(2,33)9-27-15-30-14(11-4-3-5-12(29-11)18(20,21)22)31-16(32-15)28-10-6-7-26-13(8-10)19(23,24)25/h3-8,33H,9H2,1-2H3,(H2,26,27,28,30,31,32); Key:DYLUUSLLRIQKOE-UHFFFAOYSA-N;

Enasidenib, sold under the brand name Idhifa, is an anti-cancer medication used to treat relapsed or refractory acute myeloid leukemia. It is an inhibitor of isocitrate dehydrogenase 2 (IDH2).

Common side effects of enasidenib include nausea, vomiting, diarrhea, increased levels of bilirubin (substance found in bile), and decreased appetite. Women who are pregnant or breastfeeding should not take enasidenib because it may cause harm to a developing fetus or a newborn baby.

Enasidenib was approved for medical use in the United States in August 2017. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.